Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)

摘要: LBA4509 Background: Advanced GC is an incurable disease; new and less toxic treatments are needed. HER2 overexpression has been reported in 6–35% of stomach gastroesophageal tumors. Trastuzumab (H; Herceptin), a monoclonal antibody against HER2, shown survival benefits when given with CT patients (pts) HER2-positive early metastatic breast cancer. The ToGA study the first randomized, prospective, multicenter, phase III trial to efficacy safety H HER2- positive GC. Methods: Pts gastric adenocarcinoma (locally advanced, recurrent, or metastatic) were randomized receive H+CT (5-fluorouracil capecitabine cisplatin) q3w for 6 cycles alone. was until disease progression. primary end point overall (OS); secondary points included response rate (ORR), progression-free survival, time progression, duration response, safety. An interim analysis planned at 75% deaths ...